Cerebral Toxoplasmosis and AIDS

NCT00803621 | Completed

• 1 other identifier: I07009
• Study Type: observational
• Target: 46
• Locations: 1 country
• Sites: 5

Brief Summary

With a HIV incidence much higher in the DFA than in European French territory, this disease is a major public health problem in these areas, especially in French Guiana. Cerebral toxoplasmosis is a priority among the opportunistic infections in AIDS patients from the DFA because of its frequency (French West Indies) and of its lethality (French Guiana). The diagnosis of cerebral toxoplasmosis may be difficult because based only on presumptive clinical and radiological features. The response to specific antitoxoplasmic therapy confirms a posteriori the diagnosis. In reference to the data collected by the Biological Resource Centre Toxoplasma, in particular in French Guiana, we think that T. gondii strains reactivating in AIDS patients from DFA are genetically different from those reactivating in AIDS patients from Europe, with an increased capacity for dissemination via peripheral blood in the first ones. This more frequent or more prolonged parasitemia could facilitate the diagnosis of cerebral toxoplasmosis by PCR test from peripheral blood samples in AIDS patients from the French departments of America.

Conditions

Cerebral Toxoplasmosis; AIDS

Outcome Measures

Secondary Outcomes (1)

• Isolation, genetic typing and storage of T. gondii strains collected among AIDS patients with cerebral toxoplasmosis from the DFA.

  3 years

Interventions

Toxoplasma PCR assay OTHER

Toxoplasma PCR assay

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

AIDS patients from the French West Indies and French Guiana having clinical and radiological suspicion of cerebral toxoplasmosis

You may qualify if:

• Adult patient (\> 18 years)
• Patient being informed and accepting to participate in the study with signature of informed consent
• HIV positive serology
• Clinical and radiological suspicion of cerebral toxoplasmosis justifying the start of specific antitoxoplasmic therapy

You may not qualify if:

• Protected patient
• Patient uncovered by social insurance
• Specific antitoxoplasmic therapy already initiated since 72h or more

Sponsors & Collaborators

• University Hospital, Limoges: lead

Study Sites (5)

Service des Maladies Infectieuses - CHU de Pointe à Pitre

Pointe à Pitre, Guadeloupe, France

Location

Dermatologie et CISIH- CH Andrée Rosemon

Guyane-Française, Guyane-Française, France

Location

Médecine- CH Ouest Guyanais

Guyane-Français, Guyane-Français, France

Location

Services Maladies Infectieuses et Tropicales- CHU Fort-de-France

Fort-de-France, France

Location

Maladies Infectieuses et Tropicales - CH Andrée Rosemon

Guyane-Française, France

Location

Related Publications (1)

• Ajzenberg D, Lamaury I, Demar M, Vautrin C, Cabie A, Simon S, Nicolas M, Desbois-Nogard N, Boukhari R, Riahi H, Darde ML, Massip P, Dupon M, Preux PM, Labrunie A, Boncoeur MP. Performance Testing of PCR Assay in Blood Samples for the Diagnosis of Toxoplasmic Encephalitis in AIDS Patients from the French Departments of America and Genetic Diversity of Toxoplasma gondii: A Prospective and Multicentric Study. PLoS Negl Trop Dis. 2016 Jun 29;10(6):e0004790. doi: 10.1371/journal.pntd.0004790. eCollection 2016 Jun.

  PMID: 27355620 RESULT

MeSH Terms

Conditions

Toxoplasmosis, Cerebral; Acquired Immunodeficiency Syndrome

Condition Hierarchy (Ancestors)

Brain Abscess; Central Nervous System Infections; Infections; Central Nervous System Protozoal Infections; Central Nervous System Parasitic Infections; Parasitic Diseases; Toxoplasmosis; Coccidiosis; Protozoan Infections; Abscess; Suppuration; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; HIV Infections; Blood-Borne Infections; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Slow Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Study Officials

• Daniel AJZENBERG, PharmD, PhD

  CHU Limoges

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 2, 2008
• First Posted: December 5, 2008
• Study Start: June 1, 2009
• Primary Completion: December 1, 2012
• Study Completion: December 1, 2013
• Last Updated: July 5, 2019

Record last verified: 2013-12

Locations

FR (5)